On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on the research and analysis of China's mitochondrial medicine market in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded Frost & Sullivan Partner Zeng Saiying and Dr. Gao Wenzhong, an expert consultant of the Frost & Sullivan Global Expert Advisory Group and a director of the China Enterprise M&A Association, and an executive president of Sino-Global Business Alliance, the '2025 Frost & Sullivan China Mitochondrial Medicine Industry Leadership Award' to Kangnuo Biopharmaceutical Co., Ltd. (hereinafter referred to as 'Kangnuo Biopharmaceutical').
Kangnuo Biopharmaceutical Co., Ltd.
"2025 China Mitochondrial Medicine Industry Leadership Award"
Dr. Gao Wenzhong, an expert consultant of the Frost & Sullivan Global Expert Advisory Group and a director of the All-China Federation of M&A Associations and the executive president of China Enterprise Huazhong, presented awards on behalf of Kangnuo Biopharmaceutical Co., Ltd. to Frost & Sullivan partner Zeng Saiying.
Kangnuo Biotech is a leader in mitochondrial medicine in China, driving the full-chain leapfrog development of the mitochondrial medicine industry with the dual engines of 'AI + synthetic biology'.
Kangnuo Biopharmaceutical Co., Ltd. was established in August 2017 with its headquarters located in Hefei. It is a high-tech biopharmaceutical enterprise mainly engaged in the research, development, production, and sales of mitochondrial medicine and health products. It is the first company in China to deeply integrate artificial intelligence with synthetic biology, driving the full-chain development of the mitochondrial medicine industry with 'AI + synthetic biology', focusing on NAD+anti-aging, NAD+Digital management and mitochondrial medicine research. The company holds various authoritative qualifications, including being a national-level 'specialized, refined, distinctive and innovative' small giant enterprise and a national high-tech enterprise. The company has established an end-to-end mass production platform from NAD⁺ series bulk drugs to health consumer products, achieving large-scale implementation in scenarios such as healthcare and health consumption.
The world's first "Detection-Intervention-Redetection" mitochondrial medicine closed-loop system has been implemented, setting a benchmark with cutting-edge technology.
Detection side: Relying on the independently developed aging marker detection technology and AI evaluation system, it achieves in-depth visualization and quantitative scoring of mitochondrial health status, leading the industry in terms of accuracy and dimensionality. Intervention side: It covers globally leading products such as mitochondrial nutrients, mitochondrial drugs, and mitochondrial transplantation, targeting the root causes of aging such as energy metabolism and oxidative damage. NAD+It is the 'metabolic hub' connecting aging with various diseases and a core molecule maintaining mitochondrial function. Kangnuo Biotechnology vertically integrates 'AI + synthetic biology' technology, utilizing the breakthrough in NAD+The challenge in raw material preparation was overcome, and an AI-powered NAD was built.+The 'Detection-Intervention-Recurrence Detection' full-chain solution meets the needs of different scenarios such as healthcare and wellness consumption, providing an innovative paradigm for the intervention of aging and related diseases. Kangnuo Biotechnology leverages its globally leading NAD+Detection technology, the only globally approved NAD for marketing+Medicine - Enalapril®and targeting the regulation of NAD+Metabolic anti-aging innovative drug pipelines, combined with AI platforms to achieve personalized closed-loop management of 'data-feedback-optimization', are driving the precision and accessibility of anti-aging and related disease interventions, highlighting the benchmark position of Chinese enterprises in the global field of mitochondrial medicine.
About the Frost & Sullivan China Leadership Award
The Frost & Sullivan China Leadership Award recognizes outstanding performance and achievements in technological innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team, through methods such as in-depth interviews, industry analysis, and secondary research, has nominated a group of competitive and excellent companies to an independent judging panel. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducts a rigorous review of the companies nominated by the Frost & Sullivan team and decides to award the '2025 China Mitochondrial Medicine Industry Leadership Award' to Kangnuo Biopharmaceutical Co., Ltd.
